YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
4Bio Capital Funds will advance novel class of RNA inhibitors to reverse intractable genetic conditions Seed led by 4BIO Capital with follow-on participation from the company's original pre-seed investor EXTEND (CDP Venture Capital SGR, An…
Dr. Cord Dohrmann to step down as of September 30, 2026 Search ongoing for a successor HAMBURG, Germany, Sept. 29, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that Chief Scientific Officer (…
Giovanni Amabile, Founder and CEOGiovanni Amabile, Founder and CEO of Aptadir Therapeutics Funds will advance novel class of RNA inhibitors to reverse intractable genetic conditions Seed is led by 4BIO Capital with follow-on participation…
Company Logo Pharma R&D outsourcing is rising as CROs use AI, genomics and advanced screening to cut costs, accelerate discovery, improve compliance and support targeted therapies. Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Drug Discovery…
Company Logo Stricter safety rules, drug innovation and CRO outsourcing drive demand, while imaging, CRISPR and data analytics improve testing and reduce animal use. Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "In Vivo Toxicology - Global S…
Company Logo Pharma companies are expanding drug discovery outsourcing to cut costs, access CRO expertise and AI tools, speed pipelines, manage regulatory complexity, and advance targeted therapies. Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE)…
Company Logo AI-driven screening, advanced imaging and demand for targeted therapies are accelerating FBDD, creating opportunities in oncology, neurology and traditionally undruggable targets. Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Fr…
Company Logo Automation, robotics, AI, cloud platforms and RFID are transforming compound management, creating opportunities in drug discovery, biotech, materials science and distributed research. Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) --…
Company Logo Demand is rising for faster, accurate ADME-Tox testing, driven by complex biologics, tighter regulation, personalized medicine, and adoption of high-throughput, in vitro and in silico methods. Dublin, Sept. 22, 2026 (GLOBE NEW…
Evolution (OM:EVO) confirmed that Candle Lake Limited's public offer is now unconditional following the completion of the acceptance period. The bidder is set to begin settling tendered Evolution AB shares with shareholders, following the…
First-in-human Phase 1 study initiated for investigational antibodies targeting orthopoxviruses developed under U.S. Department of War Accelerated Antibodies Program Supports development of countermeasures against orthopoxviruses, a high-p…
Collaboration aims to validate Evotec's proprietary BiTco costimulatory CD2 bispecifics platform in combination with Plectonic's logic-gated DNA-protein immunotherapy technology LOGIBODY® BiTco designed to boost T cell activation by engagi…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Odyssey Therapeutics Stock Is Back In Focus Odyssey Therapeutics (ODTX) is drawing attention after reporting second…
Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs Evotec…
Collaboration will support pharmacokinetic, pharmacodynamic, and bioanalytical studies for Niagen Bioscience's lead investigational candidate for rare pediatric diseases Evotec brings deep drug development expertise, serving leading pharma…
Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting PALO ALTO, Calif., July 23, 2026--(BUSINESS WIRE)--Navan (NASDAQ: NAVN), the global AI-powered business travel and expe…
Company Logo Opportunities span cytotoxicity, phenotypic and morphological assays, flow cytometry, and pharma and biotech demand. Asia-Pacific and Europe expansion, rare-disease models, single-cell services, and patient-derived and cardiac…
This article first appeared on GuruFocus. Group Revenue (H1 2026): EUR300.1 million, a decrease of 19% compared to H1 2025. Adjusted Group EBITDA (H1 2026): Minus EUR42.7 million. Revenue (Q2 2026): EUR143.5 million, a decrease of approxim…
Key Points Interested in Evotec AG? Here are five stocks we like better. Evotec cut its 2026 outlook after preliminary Q2 and first-half results showed weaker-than-expected revenue conversion, delayed strategic partnership revenue, and slo…
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 HAMBURG, Germany, July 13, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced preliminary unaudited fin…
(RTTNews) - Evotec SE (EVO) has introduced J.TRAIN, a turnkey solution designed to enable biopharmaceutical companies to deploy its proprietary continuous manufacturing technology directly within their own facilities. The offering combines…
Expands Just – Evotec Biologics partner-enablement and technology licensing model for proprietary continuous manufacturing platform Enables deployment of continuous manufacturing platform in partner-owned facilities to support higher produ…
11.06.2026 / 15:30 CET/CEST The issuer is solely responsible for the content of this announcement. All agenda items adopted Dieter Weinand and Dr. Wolfgang Hofmann newly elected to the Supervisory Board Dieter Weinand appointed Chairman of…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Recent share performance and business snapshot Evotec (XTRA:EVT) drew investor attention after a mi…
HAMBURG, DE / ACCESS Newswire / June 2, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Rui Wang as Executive Vice President, Head of Global In Silico and AI. Mr. Wang brings to Evotec more th…
U.S. stock futures were mixed this morning, with the Dow futures falling around 100 points on Wednesday. Shares of QuickLogic Corp(NASDAQ:QUIK) fell in pre-market trading after the company reported worse-than-expected first-quarter financi…
Shares of Nextpower Inc(NASDAQ:NXT) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results and raised its FY27 sales guidance. The company announced it will acquire assets of Zig…
Evotec SE (NASDAQ:EVO) is one of the 10 Best Penny Stocks to Buy Before They Explode. On May 4, 2026, Evotec SE (NASDAQ:EVO) announced the nomination of a small molecule preclinical development candidate from its multi-target drug discover…
* Evotec SE (EVO [https://seekingalpha.com/symbol/EVO]) on Tuesday placed senior unsecured convertible bonds due 2033, convertible into new and/or existing no-par value ordinary bearer shares of the company in an aggregate principal amount…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH, OR TO PERSONS IN ANY JURISDICTION TO WHOM, SUCH RELEASE, PUBLICATION OR DIS…
In recent weeks, the European market has experienced modest gains amid easing geopolitical tensions and strong corporate earnings, although concerns over potential U.S. tariffs on EU goods have weighed on investor sentiment. As the Europea…
In recent weeks, global markets have shown resilience, with U.S. equity markets rallying on strong corporate earnings and Japan's indices reaching record highs amid enthusiasm for AI-related demand. Despite geopolitical tensions and econom…
The European stock market recently experienced a volatile week, with modest gains in the pan-European STOXX Europe 600 Index, as investor sentiment was buoyed by easing geopolitical tensions and strong corporate earnings. However, looming…
Evotec logo Why These 3 Large Caps Are Bucking the August Slump Evotec (NASDAQ:EVO) reported first-quarter 2026 results that management said were shaped by a tough year-over-year comparison, continued softness in early drug discovery deman…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Evotec (XTRA:EVT) is back in focus after announcing that CFO Paul H…
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.3% and the actively tr PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…